C3i CEO Louisa Petropoulos was recently featured in Outsourced Pharma online, discussing the present and future prospects of contract research organizations and Canadian innovation, as well as C3i’s accomplishments upon its 5th anniversary.
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
Montreal CDMO expands beyond cell therapy manufacturing with companion diagnostics, therapeutic monitoring, and integrated patient support programs. What if every patient received a therapy tailored to their unique biology? That question, aligned with the aspirational promise of precision medicine, is now at the heart of what C3i does. The Montreal-based contract development and manufacturing organization […]
From April 7 to 9, 2026, C3i took part in the 4th Pan-Canadian Strategic Forum on Cell and Gene Therapies, organized by CellCAN at the Sheraton Laval & Convention Center. The event brought together key players in the sector, including scientists, innovators, and partners from the cell and gene therapy biomanufacturing ecosystem, around a […]
